The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! The stock decreased 2.69% or $0.12 during the last trading session, hitting $4.34. About 2.20 million shares traded hands or 16.40% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 45.54% since April 6, 2016 and is downtrending. It has underperformed by 47.50% the S&P500.
The move comes after 8 months negative chart setup for the $606.80M company. It was reported on Nov, 8 by Barchart.com. We have $3.99 PT which if reached, will make NASDAQ:ACHN worth $48.54 million less.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage
Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. Achillion Pharma has been the topic of 15 analyst reports since August 13, 2015 according to StockzIntelligence Inc. On Wednesday, May 4 the stock rating was maintained by Leerink Swann with “Market Perform”. The company was initiated on Friday, September 23 by Wedbush. The rating was initiated by FBR Capital on Thursday, September 15 with “Outperform”. On Thursday, July 14 the stock rating was initiated by Chardan Capital Markets with “Sell”. UBS upgraded the shares of ACHN in a report on Tuesday, September 8 to “Buy” rating. The firm earned “Neutral” rating on Friday, November 4 by Chardan Capital Markets. JMP Securities upgraded the shares of ACHN in a report on Thursday, July 7 to “Market Outperform” rating. The stock has “Buy” rating given by Maxim Group on Thursday, August 13. The firm has “Outperform” rating given on Friday, February 26 by Robert W. Baird. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by Jefferies on Wednesday, September 9.
According to Zacks Investment Research, “ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.08, from 0.92 in 2016Q1. The ratio increased, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
California Public Employees Retirement System has 0% invested in the company for 182,600 shares. State Board Of Administration Of Florida Retirement reported 75,246 shares or 0% of all its holdings. Columbus Circle Invsts last reported 110,174 shares in the company. The Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Jpmorgan Chase And owns 734,239 shares or 0% of their US portfolio. Proshare Advsrs Lc last reported 0.01% of its portfolio in the stock. Blackrock Inv Mgmt Lc has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Pdts Ltd accumulated 285,600 shares or 0.18% of the stock. Architects holds 0.01% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 2,300 shares. Loomis Sayles & Com Limited Partnership reported 1,416 shares or 0% of all its holdings. The Maryland-based Price T Rowe Associate Md has invested 0.01% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Orbimed Advsr Limited Liability accumulated 0.95% or 11.68M shares. Spark Inv Mgmt Limited last reported 189,400 shares in the company. Clinton Group, a New York-based fund reported 39,971 shares. Metropolitan Life Ny accumulated 83,260 shares or 0% of the stock.
ACHN Company Profile
Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.